An Analysis on Utilization Trends and Potential Savings from Dose Optimization of Antihemophilic Factor Products Based on Ideal Body Weight

Y. Liu, S. Leo, H. Makanji, S. Cutts
Magellan Rx Management, Newport, RI
AMCP Annual Meeting 2016 | San Francisco, CA

Purpose

To describe the utilization trend of antihemophilic factor products and analyze the potential savings of a dose optimization program based on ideal Body Weight (IBW) dosing in obese patients with hemophilia in a regional health plan.

Results

### Utilization Trend Analysis

<table>
<thead>
<tr>
<th>Year</th>
<th>IBW</th>
<th>Non-IBW</th>
<th>Total Cost (IBW)</th>
<th>Total Cost (Non-IBW)</th>
<th>Units per Patient (IBW)</th>
<th>Units per Patient (Non-IBW)</th>
<th>Number of Claims</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>257</td>
<td>235</td>
<td>1,838,993</td>
<td>2,661,295</td>
<td>47,875</td>
<td>65,243</td>
<td>28,910</td>
</tr>
<tr>
<td>2011</td>
<td>235</td>
<td>257</td>
<td>1,838,993</td>
<td>2,661,295</td>
<td>47,875</td>
<td>65,243</td>
<td>28,910</td>
</tr>
<tr>
<td>2012</td>
<td>257</td>
<td>235</td>
<td>1,838,993</td>
<td>2,661,295</td>
<td>47,875</td>
<td>65,243</td>
<td>28,910</td>
</tr>
<tr>
<td>2013</td>
<td>235</td>
<td>257</td>
<td>1,838,993</td>
<td>2,661,295</td>
<td>47,875</td>
<td>65,243</td>
<td>28,910</td>
</tr>
<tr>
<td>2014</td>
<td>257</td>
<td>235</td>
<td>1,838,993</td>
<td>2,661,295</td>
<td>47,875</td>
<td>65,243</td>
<td>28,910</td>
</tr>
</tbody>
</table>

### Dose Optimization Opportunity Analysis

<table>
<thead>
<tr>
<th>Dose Optimization Member Demographics</th>
<th>Total Cost (IBW)</th>
<th>Total Cost (Non-IBW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Weight (kg)</td>
<td>$33,649,504</td>
<td>$32,076,658</td>
</tr>
<tr>
<td>Normal Weight (kg)</td>
<td>$32,076,658</td>
<td>$33,649,504</td>
</tr>
<tr>
<td>Obesity (kg)</td>
<td>$41,142,172</td>
<td>$39,709,684</td>
</tr>
<tr>
<td>Obesity (kg)</td>
<td>$39,709,684</td>
<td>$41,142,172</td>
</tr>
</tbody>
</table>

Discussion

- The number of claims increased by 25% from 2010 to 2014 while number of hemophilia patients remained stable.
- Annual cost for antihemophilic factor products increased from $8,865,065 in 2010 to $10,367,173 in 2014 per million lives, which is a 16.9% increase.
- Cost per paid claims increased from $138,400 in 2010 to $160,496 in 2014.
- Noticeable utilization increases between 2010 and 2014:
  - FEIBA utilization increased by 671%.
  - von Willebrand Complex Products increased by 947%.
  - Recombinant factor products increased by 51%.
  - FEIBA utilization increased by 671%.
  - The implementation of a dose optimization program may result in approximately 11% in overall savings.
- Limitations to this study include:
  - Lack of actual member demographics; dose optimization analysis was completed using national and obesity data based on literature.
  - Trend analysis did not restrict inclusion criteria to continuously enrolled members.

Conclusion

- The cost to treat hemophilia has continued to rise in recent years leading to increased payer interest in improving management strategies.
- Dose optimization offers one unique management opportunity that may lead to provision of more cost-effective care for specific patients.
- Magellan Rx Management has developed a comprehensive hemophilia management solution that includes utilization management to ensure appropriate use of factor products and inhibitor therapy along with a dose optimization program.
- Such strategies provide an opportunity to produce significant savings for health plans while maintaining quality of care by ensuring appropriate use of factor products and inhibitor therapy.

References